ArticleJournal for immunotherapy of cancer2025

First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors.

Michele Maio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.